Category - Developments

Developments

Titan Pharma launches virtual REMS training for Probuphine health care providers

Titan Pharmaceuticals (NASDAQ:TTNP) launched a fully-virtual Probuphine implant Risk Evaluation and Mitigation Strategy (REMS) training and certification program for qualified health care providers (HCPs) who treat...

June 16, 2020

Developments

aTyr Pharma doses first patient in Phase 2 COVID-19 trial

aTyr Pharma (NASDAQ:LIFE) dosed the first patient in a Phase 2 study evaluating ATYR1923, an immunomodulator, in COVID-19 patients with severe respiratory complications. The study will enroll 30 COVID-19-positive...

June 15, 2020

Developments

Soliton posts positive pivotal cellulite trial results

Soliton (NASDAQ:SOLY) presented new positive data from the company’s pivotal cellulite clinical trial at the American Academy of Dermatology 2020 virtual conference. The trial enrolled and treated 67 subjects at four...

June 15, 2020

Developments

X4 Pharma reports positive Phase 2 mavorixafor data in WHIM syndrome

X4 Pharmaceuticals (NASDAQ:XFOR) reported positive results from its ongoing Phase 2 trial of mavorixafor for WHIM syndrome. WHIM stands for warts; hypogammaglobulinemia, or low antibody levels; infections; and...

June 12, 2020

Developments

Leap Therapeutics DKN-01 gets FDA orphan drug designation for gastric and gastroesophageal junction cancer

The FDA granted Leap Therapeutics’ (NASDAQ:LPTX) DKN-01 orphan drug designation for the treatment of gastric and gastroesophageal junction cancer. DKN-01 is a humanized monoclonal antibody that targets the Dickkopf-1...

June 12, 2020

Developments

Aprea Therapeutics updates Phase 1b/2 eprenetapopt trial results

Aprea Therapeutics (NASDAQ:APRE) reported updated data from its Phase 1b/2 trial evaluating eprenetapopt, in combination with azacytidine, for the treatment of myelodysplastic syndromes (MDS) and acute myeloidleukemia...

June 12, 2020

Developments

Analysts see EAU data broadening utility of Profound Medical’s TULSA-PRO

Analysts for Raymond James and Cowen say two posters to be presented at the European Association of Urology (EAU) virtual conference in mid-July enhance the clinical utility of Profound Medical’s (NASDAQ:PROF;...

June 11, 2020

Developments

IntelGenx pleased with FDA meeting on NDA resubmission for RIZAPORT VersaFilm

IntelGenx (TSXV:IGX; OTCQB:IGXT) obtained clarity on the chemistry, manufacturing and controls information required for the resubmission of its RIZAPORT VersaFilm NDA during its Type A meeting with the FDA on June 10...

June 11, 2020

Developments

IntelGenx to launch hand sanitizer business

Health Canada has cleared IntelGenx (TSXV:IGX; OTCQB:IGXT) to begin selling its liquid and gel hand sanitizer formulations, which will be produced using excess capacity at the company’s cGMP manufacturing facility in...

June 10, 2020

Developments

NIH Phase 2 trial of BiondVax universal flu vaccine hits both primary endpoints

A Phase 2 trial supported by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) concluded that BiondVax Pharmaceuticals’ (NASDAQ:BVXV) M-001 universal influenza vaccine candidate achieved safety and...

June 10, 2020

Category - Developments

Titan Pharma launches virtual REMS training for Probuphine health care providers

aTyr Pharma doses first patient in Phase 2 COVID-19 trial

Soliton posts positive pivotal cellulite trial results

X4 Pharma reports positive Phase 2 mavorixafor data in WHIM syndrome

Leap Therapeutics DKN-01 gets FDA orphan drug designation for gastric and gastroesophageal junction cancer

Aprea Therapeutics updates Phase 1b/2 eprenetapopt trial results

Analysts see EAU data broadening utility of Profound Medical’s TULSA-PRO

IntelGenx pleased with FDA meeting on NDA resubmission for RIZAPORT VersaFilm

IntelGenx to launch hand sanitizer business

NIH Phase 2 trial of BiondVax universal flu vaccine hits both primary endpoints

General

More